Q3 2022 Results
Company overview
Financial performance
Cardiovascular
Ophthalmology
Financial review
2022 priorities
Innovation: Pipeline overview
Immunology
Neuroscience
Global Health
libvatrep - TRPV1 antagonist
Indication
Phase
NCT04630158 SAHARA (CSAF312B12201)
Chronic ocular surface pain
Phase 2
Patients
150
Primary
Change in mean pain severity Visual Analog Scale
Outcome
Measures
Arms
Intervention
Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye
drops, twice daily
Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops,
twice daily
Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops,
twice daily
Subjects with CICP persisting at least for 4 months after refractive surgery
and chronicity confirmed during the observational period.
Target
Patients
Read-out
Milestone(s)
2023
Publication
2023
85 Investor Relations | Q3 2022 Results
Appendix
References
Innovation: Clinical trials
Abbreviations
Oncology
Other
Biosimilars
1 NOVARTIS | Reimagining MedicineView entire presentation